NMN and Inflammation: Can NAD+ Repletion Reduce Chronic Inflammation?

NMN and inflammation share a bidirectional relationship that researchers are only beginning to map with precision. When chronic low-grade inflammation takes hold — whether driven by metabolic dysfunction, aging, poor sleep, or environmental stressors — it activates two NAD+-consuming enzyme systems that progressively drain cellular NAD+ pools. As those pools fall, the anti-inflammatory sirtuin enzymes that depend on NAD+ lose activity, amplifying the inflammatory signal further. This self-reinforcing cycle is one of the more compelling mechanistic explanations for why chronic inflammation and biological aging accelerate in parallel.

Understanding this loop matters practically: it is the reason that NAD+ repletion through NMN supplementation has attracted serious scientific attention as a potential anti-inflammatory intervention — not because NMN is an anti-inflammatory drug, but because restoring NAD+ may remove one of the key substrates the cycle depends on.

The Evidence Base

The direct evidence connecting NMN to inflammation reduction in humans is limited but mechanistically coherent. The majority of available data comes from preclinical studies — mouse models of aging, diet-induced obesity, and inflammatory disease — where NMN supplementation consistently reduces circulating markers of systemic inflammation, including IL-6, TNF-alpha, and NF-kB pathway activity. These effects are reproducible across multiple independent research groups and appear dose-dependent within the ranges studied.

Key preclinical and clinical findings on NMN and inflammatory markers are summarised below.

Human trials to date have not used inflammation as a primary endpoint, but secondary outcomes from several key studies are informative. Irie et al. (2020) tested 100–500 mg NMN daily in healthy Japanese men for eight weeks and found dose-dependent increases in blood NAD+ metabolites with a favorable safety profile. The Yoshino et al. (2021) Science trial — the most cited NMN human study — tested 250 mg/day in postmenopausal women with prediabetes and found significant improvement in skeletal muscle insulin sensitivity. Prediabetes is characterized by elevated systemic inflammation, and improved insulin sensitivity is directly associated with reduced inflammatory cytokine production. Niu et al. (2023) examined serum metabolomics after short-term NMN supplementation and identified shifts in metabolic pathways relevant to oxidative stress and inflammatory regulation.

Liao et al. (2021) tested 300 mg/day NMN in recreational runners over six weeks and found improved aerobic capacity — which, while not an inflammatory endpoint, is relevant because mitochondrial NAD+ availability supports the anti-inflammatory adaptations that regular aerobic exercise produces. Gomes et al. (2013) demonstrated in a landmark Cell paper that declining NAD+ disrupts nuclear-mitochondrial communication in aging tissue, providing a foundational mechanistic context for why NAD+ repletion matters in chronically inflamed tissue.

The honest summary: no published randomized controlled trials in humans have tested NMN with inflammation as a primary measured outcome. The preclinical data is strong and consistent; the human metabolic data is suggestive but indirect. This is an area where the mechanistic rationale is considerably ahead of the direct clinical evidence.

The Mechanism: How PARP and CD38 Drain NAD+

Two enzyme systems sit at the center of the inflammation-NAD+ axis: poly ADP-ribose polymerases (PARPs) and the ectoenzyme CD38. They operate through distinct mechanisms but converge on the same outcome — rapid, sustained NAD+ consumption in inflamed tissue.

PARPs are activated by DNA strand breaks. Inflammation generates reactive oxygen species (ROS) that damage DNA, triggering PARP activation as part of the cell's repair response. Each repair cycle consumes NAD+ to generate ADP-ribose chains that serve as scaffolding for the DNA repair machinery. For acute damage, this is a necessary and well-regulated process. The problem arises under conditions of chronic inflammation: PARP activation is sustained, ROS production is continuous, and the NAD+ drain never stops. In this scenario, PARP becomes one of the primary routes through which inflammatory tissue depletes its own NAD+ reserves.

The sirtuin connection closes the loop. SIRT1, SIRT3, and SIRT6 are NAD+-dependent deacetylases with direct anti-inflammatory functions. SIRT1 suppresses NF-kB — the master transcription factor governing pro-inflammatory cytokine production — by deacetylating the RelA/p65 subunit. SIRT3 maintains mitochondrial function and reduces ROS production. SIRT6 regulates inflammatory gene expression at the chromatin level. When PARP overactivation depletes NAD+, all three sirtuins lose the substrate they need to function. With SIRT1 suppressed, NF-kB activity rises, producing more cytokines, more ROS, more DNA damage, and more PARP activation. The cycle is mechanistically self-reinforcing.

CD38: The Immune Enzyme That Amplifies NAD+ Depletion

CD38 is an ectoenzyme expressed on the surface of immune cells that degrades NAD+ to cyclic ADP-ribose and ADP-ribose as part of calcium signaling. Under normal conditions, CD38 activity is regulated. With aging and chronic inflammation, CD38 expression increases substantially — on macrophages, T cells, natural killer cells, and vascular endothelial cells. This is not a marginal effect: research in aging rodents has shown that CD38 activity can account for the majority of age-associated NAD+ decline in metabolically active tissues, often exceeding the contribution of PARP.

The connection to inflammation is direct and bidirectional. Pro-inflammatory cytokines — particularly IFN-gamma and TNF-alpha — upregulate CD38 expression on immune cells. A more inflamed tissue environment therefore means more CD38 expression, which means faster NAD+ degradation, which means less substrate available for the sirtuins that would otherwise suppress the inflammatory signal. CD38 thus acts as an inflammatory amplifier at the metabolic level.

This is distinct from the PARP mechanism and represents a parallel pathway through which chronic inflammation depletes NAD+. Studies using CD38 knockout mice have confirmed that eliminating CD38 substantially preserves NAD+ levels into aging and improves metabolic function — a finding that has motivated interest in both CD38 inhibitors and NAD+ precursor supplementation as interventions. Sirtuins and NAD+ represent the regulatory counterweight to both PARP and CD38 in this system — and their activity depends entirely on the NAD+ availability that these two enzymes consume.

NMN Supplementation and the Inflammatory Feedback Loop

The mechanistic case for NMN is direct: by replenishing NAD+ pools via the Preiss-Handler pathway, NMN restores the substrate availability that PARP and CD38 depletion has removed. With NAD+ restored, SIRT1, SIRT3, and SIRT6 resume normal activity — which includes suppressing NF-kB, reducing mitochondrial ROS production, and coordinating DNA repair. In preclinical models, this translates to measurable reductions in systemic inflammatory markers within weeks of supplementation initiation.

In mouse models of obesity and aging, NMN supplementation has consistently reduced circulating IL-6 and TNF-alpha, improved mitochondrial function in inflamed liver and adipose tissue, and attenuated the age-associated shift toward M1 macrophage polarization (the pro-inflammatory phenotype). The effect appears dose-dependent and tissue-specific in animal models, though extrapolation to human dosing remains uncertain.

In human metabolic data, the connection between stress, cortisol, and NAD+ depletion is also relevant. Psychological and physiological stress activate the HPA axis, which stimulates cortisol production and PARP activity downstream. Addressing the stress-inflammation axis at the NAD+ level is part of the theoretical rationale for NMN in chronically stressed populations. The Yoshino et al. (2021) improvement in insulin sensitivity — in a population carrying elevated inflammatory load — represents the closest we have to human evidence for this pathway operating as predicted.

For those researching the NAD+ and DNA repair connection, it is worth noting that PARP's role in both DNA repair and inflammatory NAD+ depletion means that improving cellular NAD+ availability serves both functions simultaneously — one of the more compelling arguments for NAD+ precursor supplementation in populations with high oxidative stress.

Who Benefits Most

Based on the mechanistic and preclinical evidence, the populations with the strongest rationale for NMN's potential anti-inflammatory effects are those carrying elevated baseline inflammatory burden.

Metabolic syndrome and prediabetes: Chronic hyperglycemia drives NF-kB activity, ROS production, and PARP activation continuously. This population has the most preclinical support for NAD+ repletion benefits and is closest to the human trial populations studied so far. The Yoshino 2021 trial was conducted specifically in prediabetic postmenopausal women, and the metabolic improvements observed carry indirect anti-inflammatory implications.

Adults over 50: Age-associated increases in both PARP baseline activity and CD38 expression mean that NAD+ depletion is a structural feature of aging biology, not a transient event. The NAD+ deficit in older populations is proportionally larger, meaning supplementation provides more meaningful restoration of depleted pools relative to younger, healthier individuals.

Those with chronically high inflammatory load from lifestyle factors: Poor sleep, high-glycemic diet, sedentary behavior, and chronic psychological stress all activate the PARP-CD38-sirtuin axis in ways that sustain NAD+ depletion. NMN is not a substitute for addressing these root causes, but the mechanistic rationale for supplementation as an adjunct is clearer in these populations than in optimized healthy young adults.

For those with autoimmune conditions or on immunosuppressive medications: the evidence base here is essentially nonexistent in terms of human trials. Mechanistically, restoring NAD+ could support immune regulatory function, but this is speculative and should not substitute for medical management.

Practical Takeaways

• NMN's anti-inflammatory mechanism operates through two distinct pathways — PARP (activated by inflammatory DNA damage) and CD38 (expressed by immune cells) — both of which are amplified by aging and metabolic stress.
• Human evidence for direct anti-inflammatory effects is currently indirect, derived from trials with metabolic primary endpoints. Preclinical data is consistent and mechanistically coherent across multiple independent studies.
• Populations with the highest inflammatory burden — metabolic syndrome, older adults, chronic stress — have the strongest mechanistic rationale for NAD+ repletion via NMN.
• NMN is not a replacement for addressing root causes of chronic inflammation: diet quality, sleep, exercise, and stress management all have stronger direct evidence than any supplement.
• Bio:sudo NMN 1000mg provides a full gram of NMN per serving with third-party COA for purity — relevant when targeting a specific metabolic pathway rather than general wellness.
• Morning dosing aligns NMN supplementation with the circadian peak in NAMPT (the rate-limiting NAD+ biosynthesis enzyme), potentially improving the efficiency of NAD+ repletion.

Bottom Line

The mechanistic case for NMN as an anti-inflammatory agent is coherent and supported by consistent preclinical evidence: PARP and CD38 consume NAD+ in inflamed tissue, NAD+ depletion suppresses the anti-inflammatory sirtuins, and NMN replenishment reverses this sequence in animal models. Direct human evidence for inflammation as a primary endpoint does not yet exist. The human trials conducted show NAD+ elevation and metabolic improvement in relevant populations, which carries indirect anti-inflammatory significance. NMN has the right mechanistic profile for inclusion in an anti-inflammatory protocol — but as an adjunct to foundational interventions, not a standalone solution. The evidence quality is preclinical-strong, human-limited.

References

1. Yoshino M, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224–1229. [Source]
2. Igarashi M, et al. "Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men." npj Aging. 2022;8(1):5. [Source]
3. Irie J, et al. "Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men." Endocrine Journal. 2020;67(2):153–160. [Source]
4. Liao B, et al. "Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners." J Int Soc Sports Nutr. 2021;18(1):54. [Source]
5. Gomes AP, et al. "Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging." Cell. 2013;155(7):1624–1638. [Source]
6. Niu KM, et al. "The impacts of short-term NMN supplementation on serum metabolism, fecal microbiota, and telomere length in pre-aging phase." Nutrients. 2023;15(3):755. [Source]